Package Leaflet: Information for the User
Gaduar 20mg/5mg/12.5mg film-coated tablets EFG
Gaduar 40mg/5mg/12.5mg film-coated tablets EFG
Gaduar 40mg/5mg/25mg film-coated tablets EFG
Gaduar 40mg/10mg/12.5mg film-coated tablets EFG
Gaduar40mg/10mg/25mg film-coated tablets EFG
olmesartan medoxomil/amlodipine/hydrochlorothiazide
Read the entire package leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the package leaflet
This medicine contains three active substances called olmesartan medoxomil, amlodipine (as amlodipine besylate) and hydrochlorothiazide. These three substances help control high blood pressure.
The action of these substances contributes to lowering your blood pressure. Olmesartan/hydrochlorothiazide/amlodipine is used to treat high blood pressure:
Do not takeGaduar:
Do not take this medicine if any of these conditions apply to you.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Gaduar.
Tell your doctorif you are taking any of the following medicines used to treat high blood pressure (hypertension):
Your doctor may monitor your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals.
See also the information under the heading "Do not take Gaduar".
Tell your doctorif you have any of the following health problems:
Contact your doctorif you experience any of the following symptoms:
As with any other medicine that lowers blood pressure, excessive blood pressure reduction in patients with impaired blood flow to the heart or brain may cause a heart attack or stroke. Therefore, your doctor will carefully monitor your blood pressure.
This medicine may cause an increase in lipid and uric acid levels in the blood. Your doctor will likely want to perform a blood test from time to time to monitor these possible changes.
A change in blood levels of certain chemicals called electrolytes may occur. Your doctor will likely want to perform a blood test from time to time to monitor this possible change. Some signs of electrolyte changes are: thirst, dry mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling of weakness, slowness, fatigue, drowsiness or restlessness, nausea, vomiting, decreased need to urinate, rapid heart rate. Tell your doctor if you notice any of these symptoms.
If you are going to have parathyroid function tests, you should stop taking this medicine before these tests are performed.
Use in athletes
Athletes are informed that this medicine contains a component (hydrochlorothiazide) that may result in a positive doping test.
You must inform your doctor if you are pregnant (or think you might be). This medicine is not recommended during pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken at this stage (see section "Pregnancy and lactation").
Children and adolescents
This medicine is not recommended for use in children and adolescents under 18 years of age.
Other medicines and Gaduar
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any of the following medicines, especially:
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicine.
Taking Gaduar with food, drinks, and alcohol
This medicine can be taken with or without food.
People taking this medicine should not consume grapefruit or grapefruit juice. This is because grapefruit and grapefruit juice can lead to an increase in the levels of the active ingredient amlodipine in the blood, which can cause an unpredictable increase in the blood pressure-lowering effect of Gaduar.
Be careful when drinking alcohol while taking this medicine, as some people may feel faint or dizzy. If this happens to you, do not drink any alcohol.
Elderly patients
If you are over 65 years old, your doctor will regularly monitor your blood pressure whenever your dose is increased, to ensure that your blood pressure does not drop too much.
Pregnancy and lactation
Pregnancy
You must inform your doctor if you are pregnant or think you might be. Your doctor will advise you to stop taking Gaduar before becoming pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of Gaduar. Gaduar is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if taken at this stage.
If you become pregnant while taking Gaduar, inform and consult your doctor immediately.
Breastfeeding
Tell your doctor if you are breastfeeding or about to start breastfeeding. It has been shown that amlodipine and hydrochlorothiazide pass into breast milk in small amounts. Gaduar is not recommended for mothers who are breastfeeding, and your doctor may choose another treatment if you wish to breastfeed.
If you are pregnant or breastfeeding, think you might be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medicine.
Driving and using machines
You may feel drowsy, sick, or dizzy, or have a headache while being treated for high blood pressure. If this happens, do not drive or use machines until the symptoms have disappeared. Consult your doctor.
Gaduar contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult your doctor before taking this medicine.
If you take more Gaduar than you should
If you take more tablets than you should, you will probably suffer from a drop in blood pressure, accompanied by symptoms such as dizziness, and rapid or slow heartbeat.
Excess fluid may accumulate in the lungs (pulmonary edema) causing difficulty breathing that can develop up to 24-48 hours after ingestion.
If you take more tablets than you should or if a child accidentally ingests some tablets, contact your doctor or go to the nearest emergency center immediately and bring the medicine package or this leaflet with you.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20.
If you forget to take Gaduar
If you forget to take a dose, take the usual dose the next day. Do not take a double dose to make up for forgotten doses.
If you stop treatment with Gaduar
It is important to continue taking this medicine, unless your doctor tells you to stop treatment.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If they do occur, they are usually mild and do not require treatment to be interrupted.
The following side effects may be serious, although they only affect a small number of people:
-during treatment with olmesartan/amlodipine/hydrochlorothiazide, allergic reactions with inflammation of the face, mouth and/or larynx (vocal cords), along with itching and skin rash may occur. If this happens to you, stop taking this medicine and consult your doctor immediately.
-olmesartan/amlodipine/hydrochlorothiazide may cause a pronounced drop in blood pressure in susceptible patients. This can cause fainting or severe dizziness. If this happens to you, stop taking this medicine, consult your doctor immediately, and remain lying down in a horizontal position.
-if you experience yellowing of the whites of the eyes, dark urine, itching of the skin, even if you started treatment with Olmesartan/amlodipine/hydrochlorothiazide a long time ago, contact your doctor immediately, who will evaluate your symptoms and decide how to continue with your treatment. Medicines for blood pressure (frequency not known).
Olmesartan/amlodipine/hydrochlorothiazide is a combination of three active substances. The following information describes the side effects reported so far with the combination olmesartan/amlodipine/hydrochlorothiazide (in addition to those already mentioned) and the side effects known for each of the active substances separately, or when two of the substances are taken together.
To give you an idea of the number of patients who may have side effects, they have been classified as frequent, uncommon, rare, and very rare.
These are other known side effects so far with olmesartan/amlodipine/hydrochlorothiazide:
If these effects occur, they are usually mild and do not require treatment to be interrupted.
Frequent(may affect up to 1 in 10 people)
Upper respiratory tract infection, sore throat and nose, urinary tract infection, dizziness, headache, perception of heartbeats, low blood pressure, nausea, diarrhea, constipation, cramps, swelling of the joints, feeling of urgency to urinate, weakness, swelling of the ankles, fatigue, abnormal laboratory test values.
Uncommon(may affect up to 1 in 100 people)
Dizziness when standing up, vertigo, rapid heartbeat, feeling of fainting, flushing and feeling of heat in the face, cough, dry mouth, muscle weakness, inability to have or maintain an erection.
These are the known side effects for each of the active substances separately or when two of the substances are taken together:
They may be side effects due to olmesartan/amlodipine/hydrochlorothiazide, even if they have not been observed so far with olmesartan/amlodipine/hydrochlorothiazide.
Very common(may affect more than 1 in 10 people)
Edema (fluid retention).
Frequent(may affect up to 1 in 10 people)
Bronchitis, stomach and intestine infection, vomiting, increased blood sugar, sugar in urine, confusion, drowsiness, visual disturbances (including double vision and blurred vision), nasal congestion, sore throat, difficulty breathing, cough, abdominal pain, heartburn, stomach discomfort, flatulence, joint or bone pain, back pain, bone pain, blood in urine, flu-like symptoms, chest pain, pain.
Uncommon(may affect up to 1 in 100 people)
Reduction in the number of a type of blood cells called platelets, which can cause easy bruising or prolonged bleeding, anaphylactic reactions, abnormal loss of appetite (anorexia), sleep problems, irritability, mood changes including anxiety, feeling of depression, chills, sleep disorders, alteration of the sense of taste, loss of consciousness, decreased sense of touch, feeling of tingling, worsening of myopia, ringing in the ears (tinnitus), angina (pain or unpleasant sensation in the chest, known as angina pectoris), irregular heartbeats, rash, hair loss, allergic skin inflammation, skin redness, purple spots or patches on the skin due to small hemorrhages (purpura), skin discoloration, red itchy patches (urticaria), increased sweating, itching, skin rash, skin reactions to light, such as sunburn or skin rash, muscle pain, urination problems, feeling of need to urinate at night, increased breast size in men, decreased sexual desire, facial swelling, feeling of discomfort, weight gain or loss, exhaustion.
Rare(may affect up to 1 in 1,000 people)
Inflammation and pain of the salivary glands, decrease in the number of white blood cells in the blood, which could increase the risk of infections, decrease in the number of red blood cells (anemia), bone marrow damage, restlessness, feeling of loss of interest (apathy), seizures (convulsions), yellowish perception of objects when looking at them, dry eyes, blood clots (thrombosis, embolism), fluid accumulation in the lungs, pneumonia, inflammation of blood vessels and small blood vessels in the skin, pancreatitis, yellowing of the skin and eyes, acute inflammation of the gallbladder, symptoms of lupus erythematosus such as skin rash, joint pain, and cold hands and fingers, severe skin reactions including intense skin rash, urticaria, skin redness of the body, severe itching, blisters, peeling, and skin inflammation, inflammation of the mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis), sometimes very severe, movement impairment, acute kidney failure, non-infectious kidney inflammation, decreased kidney function, fever, intestinal angioedema: swelling in the intestine that presents symptoms such as abdominal pain, nausea, vomiting, and diarrhea.
Very rare(may affect up to 1 in 10,000 people)
High muscle tension, numbness of hands or feet, heart attack, acute breathing difficulty (signs include severe breathing difficulty, fever, weakness, and confusion), stomach inflammation, gum thickening, intestinal obstruction, liver inflammation.
Side effects of unknown frequency(cannot be estimated from the available data)
Decreased vision or eye pain due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma). Tremors, rigid posture, mask-like face, slow movements, and unsteady gait. Skin and lip cancer (non-melanoma skin cancer).
Reporting of side effects
If you experience any side effects, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish Medicines Surveillance System for Human Use: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the box and the blister pack after "EXP". The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and any unused medicinal products in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medicinal products. This will help protect the environment.
Composition ofGaduar
The active ingredients are olmesartan medoxomil, amlodipine (as amlodipine besylate), and hydrochlorothiazide.
The other ingredients of the tablets are:
Appearance of the product and package contents
Gaduar 20 mg/5 mg/12.5 mg film-coated tablets are white to peach-colored, round, approximately 8 mm in diameter, with a beveled edge and the inscription "OC1" on one side and smooth on the other.
Gaduar 40 mg/5 mg/12.5 mg film-coated tablets are light yellow, round, approximately 9.5 mm in diameter, with a beveled edge and the inscription "OC2" on one side and smooth on the other.
Gaduar 40 mg/5 mg/25 mg film-coated tablets are light yellow, oval, approximately 15 mm long and 7 mm wide, with a beveled edge and the inscription "OC3" on one side and smooth on the other.
Gaduar 40 mg/10 mg/12.5 mg film-coated tablets are reddish-brown, round, approximately 9.5 mm in diameter, with a beveled edge and the inscription "OC4" on one side and smooth on the other.
Gaduar 40 mg/10 mg/25 mg film-coated tablets are reddish-brown, oval, approximately 15 mm long and 7 mm wide, with a beveled edge and the inscription "OC5" on one side and smooth on the other.
The aluminum-aluminum blister packs contain 28, 56, and 98 film-coated tablets in the box.
Only some pack sizes may be marketed.
Marketing authorization holder
Zentiva k.s.
U Kabelovny 130
102 37 Prague 10
Czech Republic
Manufacturer
LABORATORI FUNDACIÓ DAU
C/ C, 12-14 Pol. Ind. Zona Franca, Barcelona,
08040 Barcelona, Spain
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Zentiva Spain S.L.U.
Avenida de Europa, 19, Edificio 3, Planta 1.
28224 Pozuelo de Alarcón, Madrid
Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Spain: Gaduar 20 mg/5 mg/12.5 mg film-coated tablets EFG
Gaduar 40 mg/5 mg/12.5 mg film-coated tablets EFG
Gaduar 40 mg/5 mg/25 mg film-coated tablets EFG
Gaduar 40 mg/10 mg/12.5 mg film-coated tablets EFG
Gaduar 40 mg/10 mg/25 mg film-coated tablets EFG
Latvia, Lithuania, Estonia: Gaduar
Germany: Olmesartan Amlodipin HCT Zentiva 20 mg/5 mg/12.5 mg film-coated tablets
Olmesartan Amlodipin HCT Zentiva 40 mg/5 mg/12.5 mg film-coated tablets
Olmesartan Amlodipin HCT Zentiva 40 mg/5 mg/25 mg film-coated tablets
Olmesartan Amlodipin HCT Zentiva 40 mg/10 mg/12.5 mg film-coated tablets
Olmesartan Amlodipin HCT Zentiva 40 mg/10 mg/25 mg film-coated tablets
Bulgaria: ???????
Date of last revision of this leaflet: January 2025
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of GADUAR 40 MG/10 MG/12.5 MG FILM-COATED TABLETS in October, 2025 is around 22.62 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.